Topics

Articles

PBMs, wholesalers and insurers lose over $20 billion in stock value on day of announcement

Will a combination of better diagnosis resources and cost cutting lead to better patient outcomes?

Data are down for 2016-7, but still relatively high compared to prior years; UPDATED

Questions raised over how prescription dosages translate into bulk consumption; IQVIA ‘stand(s) behind our data methodologies’

Eagerly anticipated address avoids major policy changes while chipping away at well-recognized pricing disincentives

With new cellular and genetic therapies, the reimbursement process will need to evolve

Purchases totaled $19.3 billion, up 19% over 2016, say Drug Channels' Adam Fein

Move comes as drug pricing policies get heightened attention in Washington

Company celebrates its growth at annual industry event

While nominal spending was up 1.4%, actual net spending was only 0.6% greater than 2016